Psychotropic drugs and the ECG: Focus on the QTc interval

Expert Opinion on Pharmacotherapy

Volumn 3, Issue 5, 2002, Pages 479-498

  Goodnick, Paul J ^a   Jerry, Jason ^a   Parra, Francisco ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Anticonvulsant; Antidepressant; Antipsychotic; Benzodiazepine; ECG; Lithium; Psychotropic effects; QTc

Indexed keywords

AMFEBUTAMONE; AMITRIPTYLINE; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; BENZODIAZEPINE DERIVATIVE; CARBAMAZEPINE; CITALOPRAM; CLOMIPRAMINE; CLOZAPINE; DESIPRAMINE; DOXEPIN; DROPERIDOL; HALOPERIDOL; IMIPRAMINE; LITHIUM; MIRTAZAPINE; NEUROLEPTIC AGENT; NORTRIPTYLINE; OLANZAPINE; PAROXETINE; PHENOTHIAZINE DERIVATIVE; PIMOZIDE; PSYCHOTROPIC AGENT; SERTINDOLE; SERTRALINE; THIORIDAZINE; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG;

ADULT; AGE; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR PARAMETERS; CAT; CHILD; CLINICAL STUDY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE PREDISPOSITION; DRUG ADMINISTRATION ROUTE; DRUG BLOOD LEVEL; DRUG CLASSIFICATION; DRUG EFFECT; DRUG INDUSTRY; DRUG INFORMATION; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG USE; ELECTROCARDIOGRAM; FEMALE; HEART DEATH; HEART DEPOLARIZATION; HEART DISEASE; HEART INFARCTION; HEART REPOLARIZATION; HUMAN; HUMAN TISSUE; LONG QT SYNDROME; MALE; MEDICAL LITERATURE; MENTAL DISEASE; NONHUMAN; PUBLICATION; QT INTERVAL; REVIEW; RISK FACTOR; TORSADE DES POINTES;

ADOLESCENT; ADULT; AGED; ANIMALS; ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; CHILD; CLINICAL TRIALS; DRUG ADMINISTRATION SCHEDULE; ELECTROCARDIOGRAPHY; EXPERT TESTIMONY; FEMALE; HUMANS; MALE; MIDDLE AGED;

EID: 0036094878     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.3.5.479     Document Type: Review

References (112)

1. Drugs that prolong QT interval as an unwanted effect: Assessing their likelihood of inducing hazardous cardiac dysrhythmias
2. Prolonged QT interval in acute psychotic patients
3. Antipsychotic drugs, prolonged QTc interval, torsade de pointes, and sudden death
4. Cardiac effects of antipsychotic medications
5. Sudden unexplained death in psychiatric inpatients
6. Concentration-related pharmacodynamic effects of thioridazine and its metabolites in humans
7. Cardiotoxicity more common in thiordazine overdose than with other neuroleptics
8. Prolongation of QT interval in isolated feline hearts by antipsychotic drugs
9. Prolongation of the corrected QT and torsades de pointes cardiac arrhythmia associated with intravenous haloperidol in the medically ill
10. Torsade de pointes associated with the use of intravenous haloperidol
11. The association between intravenous haloperidol and torades de pointes, three cases, and a literature review
12. Torsades de pointes associated with intravenous haloperidol in critically ill patients
13. Haloperidol-induced torsade de pointes
14. The association between intravenous haloperidol and prolonged QT interval
15. ECG changes during haloperidol and pimozide treatment of Tourette's Disorder
16. Controlled study of haloperidol, pimozide, and placebo for the treatment of Gilles de la Tourette's syndrome
17. Significantly higher plasma haloperidol level during cotreatment with carbamazepine may herald cardiac change
18. Torsades de pointes ventricular tachyarrhythmia associated with haloperidol
19. Haloperidol-induced torsades de pointes
20. Life-threatening ventricular arrhythmia (torsades de pointes) after haloperidol overdose
21. Association of autonomic dysfunction and clozapine
22. Torsade de pointes resulting from the addition of droperidol to an existing cytochrome P450 drug interaction
23. Droperidol causes a dose-dependent prolongation of the QT interval
24. Effect of clarithromycin on the pharmacokinetics and pharmacodynamics of pimozide in healthy poor and extensive metabolizers of cytochrome P450 2D6 (CYP2D6)
25. Effects of newer atypical antipsychotics on autonomic neurocardiac function: A comparison between amisulpride, olanzapine, sertindole, and clozapine
26. Electrocardiographic abnormalities in patients treated with clozapine
27. Sertindole hydrochloride: A novel antipsychotic medication with a favorable side effect profile
28. Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia
29. Comparative study of mortality rates and cardiac dysrhythmias in post-marketing surveillance studies of sertindole and two other atypical antipsychotics drugs, risperidone and olanzapine
30. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders
31. Analysis of the QTc interval during olanzapine treatment of patients with schizophrenia and related psychosis
32. Risperidone overdose
33. Effect of risperidone on QT interval and QT dispersion in the elderly
34. Fatal cardiac event following initiation of risperidone therapy
35. Long term safety of long acting risperidone microspheres
36. Ziprasidone versus olanzapine in schizophrenia: Results of a double-blind study
37. A double-blind, randomized comparison of the efficacy and safety of intramuscular injections of olanzapine, lorazepam, or placebo in treating acutely agitated patients diagnosed with bipolar mania
38. Asymptomatic QTc prolongation associated with quetiapine fumarate overdose in a patient treated with risperidone
39. Acute quetiapine poisoning
40. Quetiapine, a novel antipsychotic: Experience in elderly patients with psychotic disorders
41. Multiple fixed doses of 'Seroquel' (quetiapine) in patients with acute exacerbation of chizophrenia: A comparison with haloperidol and placebo
42. Quetiapine as adjunctive treatment for adolescent mania
43. Ziprasidone overdose
44. Ziprasidone 40 and 120 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: 4 week placebo-controlled trial
45. Ziprasidone: Profile on safety
46. In vivo canine model comparison of cardiohemodynamic and electrophysiological effects of a new antipsychotic drug aripiprazole (OPC-14597) to haloperidol
47. Meta-analysis of safety and tolerability with aripiprazole
48. Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients
49. Excess risk of myocardial infarction in patients treated with antidepressant medications: Association with use of tricyclic agents
50. Depression: Treating the patient with comorbid cardiac disease
51. Tricyclic medication in children and the QT interval: Case report and discussion
52. Cardiovascular effects of tricyclic and tetracyclic antidepressants
53. The electrocardiographic and anticholinergic effects of trazodone and imipramine in man
54. Desmethylimipramine and imipramine on left ventricular function and the ECG: A randomized crossover design
55. The effect of hypericum extract on cardiac conduction as seen on the electrocardiogram compared to that of imipramine
56. Cardiovascular effects of imipramine, fluvoxamine, and placebo in depressed outpatients
57. Effect of fluoxetine on the electrocardiogram
58. Cardiovascular effects of imipramine and bupropion in aged depressed patients
59. Cardiovascular effects of desipramine in children
60. Electrocardiographic changes during desipramine and clomipramine treatment in children and adolescents
61. ECG changes in pediatric patients on tricyclic antidepressants, desipramine, and imipramine
62. Desipramine: Cardiovascular effects and plasma levels
63. 2-Hydroxydesipramine and desipramine plasma levels and electrocardiographic effects in depressed younger adults
64. ECG effects of comparable plasma concentrations of desipramine and amitriptyline
65. Effects of chronic desipramine on plasma norepinephrine concentrations and cardiovascular parameters in elderly depressed women: A preliminary report
66. Electrocardiogram changes and therapeutic desipramine and 2-hydroxydesipramine concentrations in elderly depressives
67. A retrospective study of serum levels and electrocardiographic effects of nortriptyline in children and adolescents
68. Plasma levels of nortriptyline and 10-hydroxynortriptyline and treatment-related electrocardiographic changes in the elderly depressed
69. Electrocardiographic changes with nortriptyline and 10-hydroxynortriptyline in elderly depressed outpatients
70. Cardiovascular effects of fluoxetine in depressed patients with heart disease
71. The cardiovascular effects of bupropion and nortriptyline in depressed outpatients
72. Tricyclic neuroleptic and antidepressant overdose: Epidemiological, electrocardiographic, and clinical features - A survey of 92 cases
73. Comparison of the effects of bupropion and amitriptyline on cardiac conduction in depressed patients
74. Comparative effects of fluoxetine and amitriptyline on cardiac function
75. Cardiovascular effects of amitriptyline, mianserin, zimelidine, and nomifensine in depressed patients
76. Electrocardiographic effects of tranylypromine versus amitriptyline
77. Cardiovascular effects of phenelzine and amitriptyline in depressed outpatients
78. Electrophysiolgical and haemodynamic changes with trazodone, amitriptyline, and placebo in depressed outpatients
79. Electrocardiographic effects of fluoxetine and doxepin in patients with major depressive disorder
80. Cardiovascular effects of fluvoxamine and maprotiline in depressed patients
81. The role of trazodone in the treatment of depressed cardiac patients
82. The electrocardiogram as a tool for therapeutic monitoring: A critical analysis
83. Absence of cardiovascular adverse effects of sertraline in children and adolescents
84. An open-label preliminary trial of sertraline for treatment of major depression after acute myocardial infarction
85. Sertraline treatment of MDD in pts with acute MI or unstable angina
86. Comparison of some effects of paroxetine with amitriptyline on the cardiovascular system in animals
87. Cardiovascular effects of paroxetine, a newly developed antidepressant, in anesthetized dogs in comparison with those of imipramine, amitriptyline, and clomipramine
88. Paroxetine: Pharmacokinetics and cardiovascular effects after oral and intravenous single doses in man
89. Paroxetine does not affect the cardiac safety and pharmacokinetics of terfenadine in healthy adult men
90. The safety profile of paroxetine
91. Effect of paroxetine on the electrocardiogram
92. Cardiovascular effects of paroxetine
93. Comparison of paroxetine and nortriptyline in depressed patients with ischemic heart disease
94. A comparative pharmacodynamic study of the arrhythmogenicity of antidepressants, fluvoxamine and imipramine, in guinea pigs
95. Cardiac effects of antidepressant drugs. A comparison of the tricyclic antidepressants and fluvoxamine
96. QTc interval prolongation associated with citalopram overdose: A case report and literature review
97. Cardiac safety of citalopram: Prospective trials and retrospective analyses
98. Cardiovascular safety in depressed patients: Focus on venlafaxine
99. Cardiotoxicity associated with bupropion overdose
100. Cardiovascular effects of bupropion in depressed patients with heart disease
101. Medical Economics
102. Efficacy of mirtazapine for prevention of depressive relapse: A placebo-controlled double-blind trial of recently remitted high-risk patients
103. Mirtazapine in treatment of depression in patients with ischaemic heart disease
104. ECG changes during lithium therapy
105. Cardiac effects of lithium therapy in man: A review
106. Prolongation of the QT interval in lithium toxicity
107. Cardiotoxic side effects of valproate
108. Electrophysiological evaluation of the sodium channel blocker carbamazepine in healthy human subjects
109. Carbamazepine-induced cardiac dysfunction
110. Placebo-controlled study of the efficacy and safety of lamotrigine in patients with partial seizures
111. QT interval of the ECG, heart rate and arterial pressure using propofol, methohexital or midazolam for induction of anesthesia
112. The effects of midazolam or propofol followed by suxamethonium on the QT interval in humans